Elevated Lp(a) levels were associated with greater risk of MACE in optimally treated patients with high-risk vascular disease when hsCRP levels ≥2 mg/L, but not in those with hsCRP levels <2 mg/L.

Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.

This study showed that incorporation of genetic testing results in increased numbers of patients diagnosed with definite FH, compared to classification based solely on clinical criteria.

This phase 2 study with alirocumab decreased LDL-c levels and was generally well tolerated in pediatric HeFH patients. Two dosing regimens were selected for further investigation in a phase 3 trial.

Statins lowered total cholesterol, LDL-c, triglycerides and apo-B levels and increased HDL-c levels in children and adolescents with FH, as shown in this systematic review and meta-analysis.

Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

Elevated TRL-c levels were associated with increased risk of MI and PAD in women, whereas high sdLDL-c levels were associated with increased risk of MI alone, as shown in a case-cohort study.

Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.

High intake of sugar-sweetened beverages was associated with adverse changes in HDL-c and triglyceride, along with higher incidence of dyslipidemias related to low HDL-c and high triglyceride.

This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.

Jorge Plutzky talks about an approach implemented in the Brigham and Women's Hospital, that uses an algorithm to select type of medication per individual to achieve target LDL-c levels.